WALTHAM, Mass.--(BUSINESS WIRE)--Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced the immediate availability of version 2.5 of the company’s Clinical Trials Signal Detection (CTSD™) system. A comprehensive tool for detecting, evaluating and tracking potential safety signals, CTSD 2.5 provides an enhanced user interface with clear summary displays, a wide selection of data visualization tools and the ability to easily access trial data without programming.
